Fol. Biol. 2003, 49, 74-77
https://doi.org/10.14712/fb2003049020074
A Prospective Open-Label Single-Arm Phase II Study of Chimeric Monoclonal Antibody cG250 in Advanced Renal Cell Carcinoma Patients
References
1. Association of demographic cancer-register in Germany (2002) Cancer in Germany. Saarbrücken.
2. 2001) IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br. J. Cancer 85, 1130-1136.
< , J., Kirchner, H., Illiger, H. J., Metzner, B., Ukena, D., Schott, H., Funke, P. J., Gramatzki, M., Jurgenson, S., Wandert, T., Patzelt, T., Reitz, M. (https://doi.org/10.1054/bjoc.2001.2076>
3. 1989) Monoclonal antibodies to renal cancer antigens. Semin. Urol. 7, 264-270.
, N. H. (
4. 1988) Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cancer: isolation, characterization, and antitumor activity. Cancer Res. 48, 206-210.
, A., Muul, L. M., Rosenberg, S. A. (
5. 2001) Cytokine therapy for metastatic renal cell carcinoma. Semin. Urol. Oncol. 19, 148-154.
, R. M. (
6. 1980) The diagnosis and treatment of renal cell carcinoma. Cancer 45, 1947-56.
< , J. B., Berry, D. (https://doi.org/10.1002/cncr.1980.45.s7.1947>
7. 1991) Complete spontaneous regression in metastatic renal cell carcinoma - an update and review. World J. Urol. 9, 184-191.
< , W., Allhoff, E., Kirchner, H., Stief, C. G., Atzpodien, J., Maschek, H., Jonas, U. (https://doi.org/10.1007/BF00182838>
8. 2001) Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 19, 833-841.
< , R. O. (https://doi.org/10.1081/CNV-100107745>
9. 1988) Results of surgical treatment of renal cell carcinoma with solitary metastasis. J. Urol. 140, 277-279.
< , M. K., Pastore, R. D., Emrich, L. J., Huben, R. P. (https://doi.org/10.1016/S0022-5347(17)41582-5>
10. 1986) Aggressive treatment of metastatic renal cancer. J. Urol. 136, 805-807.
< , M., Al-Askari, S., Tessler, A., Morales, P. (https://doi.org/10.1016/S0022-5347(17)45085-3>
11. 2002) Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. Urology 60, 357-362.
< , K., de Weijert, M., Uemura, H., Schalken, J., Oosterwijk, E. (https://doi.org/10.1016/S0090-4295(02)01711-9>
12. 1989) Immunotherapy of renal cell carcinoma. Semin. Urol. 7, 215-227.
, S. D. (
13. 1991) Immunomodulation of advanced/progressive renal cell carcinoma. Curr. Opin. Urol. 1, 38-46.
< , R., Ackermann, R. (https://doi.org/10.1097/00042307-199110000-00011>
14. 2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6, 34-55.
< , E., Haluska, F. G. (https://doi.org/10.1634/theoncologist.6-1-34>
15. 1995) Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824-832.
< , T. M., Motzer, R. J., Mazumdar, M., Sell, K. W., Walther, P. J., O'Connell, M., Khan, A., Vlamis, V., Vogelzang, N. J., Bajorin, D. F. (https://doi.org/10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N>
16. 2001) Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature. Eur. J. Clin. Pharmacol. 57, 267-273.
< , M., Ferlito, L., Gulizia, G., Di Fazio, I., Pistone, G. (https://doi.org/10.1007/s002280100321>
17. 1983) Immunologic therapies of kidney carcinoma. Semin. Oncol. 104, 431-436.
, C. S. (
18. 1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 338, 1272-1278.
< , S., Escudier, B., Lasset, C., Douillard, J. Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., Tursz, T. (https://doi.org/10.1056/NEJM199804303381805>
19. 2000) Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J. Sci. Am. 6 (suppl. 1), S93-S98.
, S., Maral, J., Drevon, M., Vinke, J., Escudier, B., Philip, T. (
20. 1986) Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38, 489-494.
< , E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., Warnaar, S. O. (https://doi.org/10.1002/ijc.2910380406>
21. 1993) Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol. 11, 738-750.
< , E., Bander, N. H., Divgi, C. R., Welt, S., Wakka, J. C., Finn, R. D., Carswell, E. A., Larson, S. M., Warnaar, S. O., Fleuren, G. J. (https://doi.org/10.1200/JCO.1993.11.4.738>
22. 1995) Radiolabeled monoclonal antibody G250 in renal-cell carcinoma. World J. Urol. 13, 186-190.
< , E., Debruyne, F. M. (https://doi.org/10.1007/BF00184877>
23. 1995) The use of monoclonal antibody G250 in the therapy of renalcell carcinoma. Semin. Oncol. 22, 34-41.
, E., Debruyne, F. M., Schalken, J. A. (
24. 2002) Epidermal growth factor receptor and G250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? J. Urol. 167, 707-712.
< , H., Stockmeyer, B., Kuhn, R., Schrott, K. M., Kalden, J. R., Glennie, M. J., van de Winkel, J. G., Gramatzki, M., Valerius, T., Elsasser, D. (https://doi.org/10.1016/S0022-5347(01)69131-6>
25. 1994) Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int. J. Cancer 56, 262-268.
< , J., Uemura, H., Beniers, A. J., Peelen, W. P., Zegveld, S. T., Fleuren, G. J., Warnaar, S. O., Oosterwijk, E. (https://doi.org/10.1002/ijc.2910560220>
26. 1993) Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells. J. Immunol. 151, 6429-6439.
< , B. A., Huizinga, T. W., Wardwell, K., Guyre, P. M. (https://doi.org/10.4049/jimmunol.151.11.6429>
27. 2001) Combination of local and systemic cytokine-therapy in metastatic renal cell carcinoma. Eur. Urol. 39 (suppl. 5), 123 (482).
, Z., Hegele, A., von Knobloch, R., Heidenreich, A., Hofmann, R. (
28. 1948) Optimum character of the sequential probability ratio test. Ann. Math. Stat. 19, 326-339.
< , A., Wolfowitz, J. (https://doi.org/10.1214/aoms/1177730197>
29. 1950) Bayes solutions of sequential decision problems. Ann. Math. Stat. 21, 82-99.
< , A., Wolfowitz, J. (https://doi.org/10.1214/aoms/1177729887>
30. 1999) Monoclonal antibody therapy of cancer. Semin. Oncol. 26 (suppl. 14), 43-51.
, L. M. (